These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38949880)

  • 41. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
    Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
    Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
    Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
    Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial.
    Ceriello A; Ofstad AP; Zwiener I; Kaspers S; George J; Nicolucci A
    Cardiovasc Diabetol; 2020 Oct; 19(1):176. PubMed ID: 33050931
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
    Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Blais J; Li Q; Jardine MJ; Perkovic V; Wheeler DC
    Am J Kidney Dis; 2021 Jan; 77(1):23-34.e1. PubMed ID: 32971190
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
    Packer M; Anker SD; Butler J; Filippatos G; Pocock SJ; Carson P; Januzzi J; Verma S; Tsutsui H; Brueckmann M; Jamal W; Kimura K; Schnee J; Zeller C; Cotton D; Bocchi E; Böhm M; Choi DJ; Chopra V; Chuquiure E; Giannetti N; Janssens S; Zhang J; Gonzalez Juanatey JR; Kaul S; Brunner-La Rocca HP; Merkely B; Nicholls SJ; Perrone S; Pina I; Ponikowski P; Sattar N; Senni M; Seronde MF; Spinar J; Squire I; Taddei S; Wanner C; Zannad F;
    N Engl J Med; 2020 Oct; 383(15):1413-1424. PubMed ID: 32865377
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial.
    Inzucchi SE; Khunti K; Fitchett DH; Wanner C; Mattheus M; George JT; Ofstad AP; Zinman B
    J Clin Endocrinol Metab; 2020 Sep; 105(9):3025-35. PubMed ID: 32485734
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME.
    Verma S; Mazer CD; Inzucchi SE; Wanner C; Ofstad AP; Johansen OE; Zwiener I; George JT; Butler J; Zinman B
    Diabetes Obes Metab; 2021 May; 23(5):1173-1181. PubMed ID: 33502090
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.
    Fitchett D; Zinman B; Wanner C; Lachin JM; Hantel S; Salsali A; Johansen OE; Woerle HJ; Broedl UC; Inzucchi SE;
    Eur Heart J; 2016 May; 37(19):1526-34. PubMed ID: 26819227
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
    Barnett AH; Mithal A; Manassie J; Jones R; Rattunde H; Woerle HJ; Broedl UC;
    Lancet Diabetes Endocrinol; 2014 May; 2(5):369-84. PubMed ID: 24795251
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.
    Verma S; Sharma A; Zinman B; Ofstad AP; Fitchett D; Brueckmann M; Wanner C; Zwiener I; George JT; Inzucchi SE; Butler J; Mazer CD
    Diabetes Obes Metab; 2020 Jul; 22(7):1141-1150. PubMed ID: 32227432
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
    Ferreira JP; Kraus BJ; Zwiener I; Lauer S; Zinman B; Fitchett DH; Koitka-Weber A; George JT; Ofstad AP; Wanner C; Zannad F
    J Am Heart Assoc; 2021 Apr; 10(7):e020053. PubMed ID: 33754809
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
    Packer M; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Anker SD; Zannad F;
    Eur J Heart Fail; 2019 Oct; 21(10):1270-1278. PubMed ID: 31584231
    [TBL] [Abstract][Full Text] [Related]  

  • 55. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial.
    Voors AA; Damman K; Teerlink JR; Angermann CE; Collins SP; Kosiborod M; Biegus J; Ferreira JP; Nassif ME; Psotka MA; Tromp J; Brueckmann M; Blatchford JP; Salsali A; Ponikowski P;
    Eur J Heart Fail; 2022 Oct; 24(10):1844-1852. PubMed ID: 36066557
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.
    Fitchett D; Butler J; van de Borne P; Zinman B; Lachin JM; Wanner C; Woerle HJ; Hantel S; George JT; Johansen OE; Inzucchi SE;
    Eur Heart J; 2018 Feb; 39(5):363-370. PubMed ID: 29020355
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
    Fitchett D; Inzucchi SE; Cannon CP; McGuire DK; Scirica BM; Johansen OE; Sambevski S; Kaspers S; Pfarr E; George JT; Zinman B
    Circulation; 2019 Mar; 139(11):1384-1395. PubMed ID: 30586757
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
    Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
    Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
    Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.